Attached files

file filename
10-K - FORM 10-K - REGENERX BIOPHARMACEUTICALS INCc98562e10vk.htm
EX-32.2 - EXHIBIT 32.2 - REGENERX BIOPHARMACEUTICALS INCc98562exv32w2.htm
EX-31.1 - EXHIBIT 31.1 - REGENERX BIOPHARMACEUTICALS INCc98562exv31w1.htm
EX-23.1 - EXHIBIT 23.1 - REGENERX BIOPHARMACEUTICALS INCc98562exv23w1.htm
EX-31.2 - EXHIBIT 31.2 - REGENERX BIOPHARMACEUTICALS INCc98562exv31w2.htm
EX-10.25 - EXHIBIT 10.25 - REGENERX BIOPHARMACEUTICALS INCc98562exv10w25.htm
         
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of RegeneRx Biopharmaceuticals, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, J.J. Finkelstein, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
  (1)  
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
  (2)  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in this report.
This certification accompanies this Report to which it relates, shall not be deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.
Date: March 31, 2010
         
  /s/ J.J. Finkelstein    
  J.J. Finkelstein   
  President and Chief Executive Officer (Principal Executive Officer)